Impact of Xenazine (Tetrabenazine) on Gait and Functional Activity in Individuals With Huntington's Disease.

Trial Profile

Impact of Xenazine (Tetrabenazine) on Gait and Functional Activity in Individuals With Huntington's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 May 2013

At a glance

  • Drugs Tetrabenazine (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top